Showing results (2371-2380 of 2,890) with videos related to

Sort By:
Pageof 289
Science (New York, N.Y.)|August 15, 1997
AIB1, a steroid receptor coactivator amplified in breast and ovarian cancerS L Anzick, J Kononen, R L Walker, et al.
Cancer Cytopathology|October 24, 2018
Cytologic patterns of cervical adenocarcinomas with emphasis on factors associated with underdiagnosisRachel D Conrad, Angela H Liu, Nicolas Wentzensen, et al.
Gynecologic Oncology|May 23, 2008
Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?Kathleen N Moore, Monica S Reid, Daniel N Fong, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 17, 2009
Ultrastructural and morphological analyses of the in vitro and in vivo hemostatic effects of Ankaferd Blood StopperBerat Z Haznedaroglu, Ibrahim C Haznedaroglu, Sharon L Walker, et al.
Journal of Alzheimer'S Disease : JAD|April 29, 2017
Use of Analgesics (Opioids and Nonsteroidal Anti-Inflammatory Drugs) and Dementia-Related Neuropathology in a Community-Based Autopsy CohortSascha Dublin, Rod L Walker, Shelly L Gray, et al.
The Journal of Investigative Dermatology|August 25, 2005
Measurement of sunscreen immune protection factors in humans: a consensus paperAnny Fourtanier, Dominique Moyal, Jean Maccario, et al.
Journal of Medical Genetics|November 14, 2006
Zoom-in comparative genomic hybridisation arrays for the characterisation of variable breakpoint contiguous gene syndromesJennifer J Johnston, Robert L Walker, Sean Davis, et al.
Experimental Neurology|April 8, 2009
Ventricular dilation and elevated aqueductal pulsations in a new experimental model of communicating hydrocephalusM E Wagshul, J P McAllister, S Rashid, et al.
Plos One|May 24, 2011
Preferential localization of human origins of DNA replication at the 5'-ends of expressed genes and at evolutionarily conserved DNA sequencesManuel S Valenzuela, Yidong Chen, Sean Davis, et al.
Gynecologic Oncology|September 5, 2018
Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group studyWilliam P Tew, Michael W Sill, Joan L Walker, et al.
Pageof 289